Clinical research
Today’s data describes key safety and immunogenicity data from the U.S. Phase I study for BNT162b.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
“We are grateful to the NIA for their rigorous scientific review and funding support to advance ALZ-8801 for Alzheimer’s patients in need of an effective treatment,” said Martin Tolar, founder, president and chief executive officer of Alzheon.
Despite the urgent need for more research into the coronavirus, the New York Times reported on August 14 that there have been numerous testing delays, staffing shortages and space constraints tying up the process.
Shares of Poseida Therapeutics plunged more than 20% in premarket trading this morning after the company announced the U.S. Food and Drug Administration halted a cancer drug trial due to safety concerns.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
The 11-person team at Codagenix may be tiny, but it has big plans for the company’s new COVID-19 vaccine.
UNITY Biotechnology reported that the 12-week results from its Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
Phase III clinical trials for Russia’s Sputnik V vaccine for COVID-19 began Wednesday, one day after the Russia Direct Investment Fund (RDIF) launched a new website to share the details of the vaccine with the public and scientists around the world.
PRESS RELEASES